💨 Abstract

Biotech firm MediWound Ltd. reported a Q2 loss of $13.3 million, or $1.23 per share, missing analyst expectations of a loss of 55 cents per share. However, the company's revenue of $5.7 million beat the forecasted $5.6 million. MediWound specializes in treatments for burns and hard-to-heal wounds.

Courtesy: WTOP Staff